Loading
Melanoma and kidney cancer trialist who co-led CheckMate 067, the trial with 10-year immunotherapy survival data.
James Larkin is a consultant medical oncologist at The Royal Marsden and Professor at The Institute of Cancer Research. His specialisms are melanoma, renal cell carcinoma and immunotherapy combinations. He was a lead investigator of CheckMate 067, the trial of nivolumab plus ipilimumab in advanced melanoma, and of CheckMate 9ER in renal cell carcinoma, work that shaped first-line immunotherapy in both diseases. His New England Journal of Medicine paper reported the long-term results of combined nivolumab and ipilimumab in advanced melanoma from CheckMate 067. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Five-year survival with combined nivolumab and ipilimumab in advanced melanoma (CheckMate 067) | NEJM | 2019 |
| CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later | New England Journal of Medicine | 2025 |
| CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma | New England Journal of Medicine | 2025 |
Shares coBRIM, CheckMate 238, CheckMate 067, Ipilimumab.
Shares CheckMate 067, CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma, Advanced melanoma (unresectable stage III and stage IV), Ipilimumab.
Shares CheckMate 067, CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma, Advanced melanoma (unresectable stage III and stage IV), Ipilimumab.
Shares CheckMate 067, Advanced melanoma (unresectable stage III and stage IV), Ipilimumab, Nivolumab.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab, Melanoma.
Shares CheckMate 238, Ipilimumab, Nivolumab.
Shares CheckMate 067, CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma, Advanced melanoma (unresectable stage III and stage IV), Nivolumab.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab.